

Lisa F Licitra

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7479322/lisa-f-licitra-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264
papers

16,717
citations

56
h-index

125
g-index

278
ext. papers

20,715
ext. citations

5.7
avg, IF

6.1
L-index

#	Paper	IF	Citations
264	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016 , 375, 1856-1867	59.2	2647
263	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 394, 1915-1928	40	839
262	Cabozantinib in progressive medullary thyroid cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3639-46	2.2	762
261	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 393, 156-167	40	674
260	High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5630-6	2.2	531
259	Rare cancers are not so rare: the rare cancer burden in Europe. <i>European Journal of Cancer</i> , 2011 , 47, 2493-511	7.5	398
258	Motesanib diphosphate in progressive differentiated thyroid cancer. <i>New England Journal of Medicine</i> , 2008 , 359, 31-42	59.2	397
257	Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v184-6	10.3	391
256	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018 , 81, 45-51	4.4	372
255	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2013 , 14, 697-710	21.7	343
254	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1864-71	2.2	303
253	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 583-94	21.7	293
252	Major and minor salivary gland tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 134-48	7	254
251	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EURO CARE-5 population-based study. <i>European Journal of Cancer</i> , 2015 , 51, 2130-2143	7.5	250
250	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1104-1115	21.7	232
249	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) 2019 , 7, 184		223
248	Systemic therapy in the palliative management of advanced salivary gland cancers. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2673-8	2.2	223

247	Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 142-52	9.7	215
246	Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 327-33	2.2	192
245	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. <i>Annals of Oncology</i> , 2011 , 22, 1078-1087	10.3	182
244	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncology, The</i> , 2015 , 16, 729-36	21.7	161
243	Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. <i>Annals of Oncology</i> , 2014 , 25, 801-807	10.3	159
242	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 44-53	12.9	152
241	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009 , 45, 574-8	4.4	150
240	Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii83-5	10.3	149
239	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 323-335	21.7	133
238	Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 6643-51	12.9	133
237	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. <i>Cancer</i> , 2015 , 121, 2749-56	6.4	130
236	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. <i>European Journal of Cancer</i> , 2013 , 49, 1161-8	7.5	128
235	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009 , 45, 986-90	4.4	111
234	Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. <i>Thyroid</i> , 2014 , 24, 232-40	6.2	108
233	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 74362-74379	3.3	104
232	Smoothed (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. <i>Molecular Oncology</i> , 2015 , 9, 389-97	7.9	103
231	TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 761-6	2.2	92
230	Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. <i>Oncologist</i> , 2016 , 21, 1218-1229	5.7	86

229	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2017 , 7, 72	5.3	86
228	Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4901-6	2.2	86
227	Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. <i>Cancer</i> , 1991 , 68, 1874-7	6.4	86
226	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. <i>Head and Neck</i> , 2016 , 38, 724-31	4.2	82
225	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012 , 23, 1832-7	10.3	82
224	Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. <i>Cancer</i> , 2014 , 120, 2694-703	6.4	81
223	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , 2017 , 22, 1056-1066	5.7	80
222	Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015 , 51, 271-81	7.5	80
221	TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>International Journal of Cancer</i> , 2003 , 105, 196-203	7.5	79
220	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. <i>Oncotarget</i> , 2015 , 6, 9627-42	3.3	79
219	Cancer of the larynx. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 47, 65-80	7	76
218	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 372-84	7	75
217	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019 , 25, 5221-5230	12.9	74
216	Survival from salivary glands adenoid cystic carcinoma in European populations. <i>Oral Oncology</i> , 2009 , 45, 669-74	4.4	72
215	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. <i>Oral Oncology</i> , 2017 , 66, 58-63	4.4	70
214	Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. <i>Cancer Research</i> , 2015 , 75, 1205-15	10.1	63
213	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 1227-39	3.5	62
212	Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. <i>Oral Oncology</i> , 2016 , 59, 73-79	4.4	61

211	Major and minor salivary glands tumours. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 45, 215-25	7	60
210	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. <i>Annals of Oncology</i> , 2014 , 25, 462-6	10.3	58
209	Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 774-7; author reply 777-8	6.7	56
208	Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. <i>Clinical Cancer Research</i> , 2014 , 20, 6570-81	12.9	55
207	An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 5508-5508	2.2	54
206	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016 , 22, 3961-70	12.9	53
205	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015 , 26, 300-6	10.3	51
204	Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009 , 20 Suppl 4, 121-2	10.3	50
203	A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. <i>Annals of Oncology</i> , 2003 , 14, 1327-8	10.3	50
202	Cancer of the oropharynx. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 41, 107-22	7	48
201	Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. <i>Annals of Oncology</i> , 2003 , 14, 367-72	10.3	48
200	Management of salivary gland tumors. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1161-8	3.5	47
199	Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). <i>European Journal of Cancer</i> , 2008 , 44, 2542-5	7.5	46
198	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
197	Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 99, 100-6	7	45
196	Cancer of the nasopharynx. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 45, 199-213	7	45
195	Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 2596-603	7.5	44
194	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016 , 69, 158-165	7.5	44

193	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018 , 23, 1079-1082	5.7	44
192	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019 , 125, 3208-3218	6.4	44
191	Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III. <i>Head and Neck</i> , 2015 , 37, 1358-67	4.2	44
190	Rare cancers of the head and neck area in Europe. <i>European Journal of Cancer</i> , 2012 , 48, 783-96	7.5	44
189	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. <i>Annals of Oncology</i> , 2012 , 23, 435-41	10.3	42
188	Oropharyngeal cancer - is it time to change management according to human papilloma virus status?. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012 , 20, 120-4	2	42
187	Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. <i>Oral Oncology</i> , 2005 , 41, 890-4.4	4.4	42
186	Effects of treatment intensification on acute local toxicity during radiotherapy for head and neck cancer: prospective observational study validating CTCAE, version 3.0, scoring system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 330-7	4	41
185	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 848-857	21.7	40
184	Lung metastasectomy in adenoid cystic cancer: Is it worth it?. <i>Oral Oncology</i> , 2017 , 65, 114-118	4.4	39
183	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017 , 28, 2820-2826	10.3	39
182	Acute skin toxicity management in head and neck cancer patients treated with radiotherapy and chemotherapy or EGFR inhibitors: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 167-82	7	39
181	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 57-75	5.5	39
180	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. <i>Oral Oncology</i> , 2016 , 54, 54-7	4.4	39
179	Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. <i>Annals of Oncology</i> , 2014 , 25, 1628-35	10.3	39
178	Best practices in the management of the psycho-oncologic aspects of head and neck cancer patients: recommendations from the European Head and Neck Cancer Society Make Sense Campaign. <i>Annals of Oncology</i> , 2014 , 25, 2115-2124	10.3	38
177	RET inhibition: implications in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 403-19	6.4	36
176	Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v187-9	10.3	36

175	A new classification for malignant tumors involving the anterior skull base. <i>JAMA Otolaryngology</i> , 1999 , 125, 1252-7		36
174	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. <i>Head and Neck</i> , 2019 , 41, 1725-1737	4.2	36
173	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. <i>Cancer</i> , 2012 , 118, 4694-705	6.4	34
172	Human papillomavirus in HNSCC: a European epidemiologic perspective. <i>Hematology/Oncology Clinics of North America</i> , 2008 , 22, 1143-53, vii-viii	3.1	34
171	Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. <i>Annals of Oncology</i> , 2016 , 27, 1585-93	10.3	33
170	Further improvement in outcomes of nasopharyngeal carcinoma with optimized radiotherapy and induction plus concomitant chemotherapy: an update of the Milan experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 774-80	4	33
169	Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients. <i>Endocrine-Related Cancer</i> , 2018 , 25, 217-231	5.7	32
168	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. <i>Oral Oncology</i> , 2013 , 49, 413-9	4.4	32
167	Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 1053-9	4	32
166	Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1856-1864	2.2	31
165	An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. <i>Cancer</i> , 2014 , 120, 390-8	6.4	30
164	Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). <i>Quality of Life Research</i> , 2000 , 9, 151-9	3.7	30
163	Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>Head and Neck</i> , 2006 , 28, 909-15	4.2	29
162	Salvage surgery of cervical recurrences after neck dissection or radiotherapy. <i>Head and Neck</i> , 1993 , 15, 292-5	4.2	29
161	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 959-966	4	28
160	Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 191-213	7	28
159	p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. <i>Cancer</i> , 2007 , 109, 2461-5	6.4	28
158	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. <i>Annals of Oncology</i> , 2014 , 25, 694-699	10.3	27

157	Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. <i>Current Opinion in Oncology</i> , 2013 , 25, 224-8	4.2	27
156	Management of Salivary Gland Malignancy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1909-1941		27
155	Long-term update of the 24954 EORTC phase III trial on larynx preservation. <i>European Journal of Cancer</i> , 2016 , 65, 109-12	7.5	26
154	Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2013 , 49, 2877-83	7.5	25
153	Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. <i>Future Oncology</i> , 2015 , 11, 703-12	3.6	25
152	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011 , 22, 2495-2500	10.3	25
151	Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study. <i>Thyroid</i> , 2016 , 26, 1605-1613	6.2	25
150	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018 , 65, 78-86	14.4	24
149	Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. <i>Cancer Epidemiology</i> , 2014 , 38, 670-8	2.8	24
148	Is there still a role for neoadjuvant chemotherapy in head and neck cancer?. <i>Annals of Oncology</i> , 2004 , 15, 7-11	10.3	24
147	Salivary Gland Cancer: An Update on Present and Emerging Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 257-263	7.1	24
146	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019 , 96, 7-14	4.4	23
145	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Future Oncology</i> , 2013 , 9, 103-14	3.6	23
144	Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. <i>International Journal of Cancer</i> , 1998 , 79, 619-23	7.5	22
143	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. <i>Annals of Oncology</i> , 2007 , 18, 601-2	10.3	22
142	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. <i>Oncotarget</i> , 2017 , 8, 47780-47789	3.3	22
141	Big Data in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 62	5.4	22
140	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. <i>Cancer</i> , 2020 , 126, 1888-1894	6.4	21

139	Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. <i>Cancer Treatment Reviews</i> , 2018 , 69, 164-176	14.4	21
138	The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. <i>Frontiers in Oncology</i> , 2019 , 9, 668	5.3	21
137	Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer. <i>Genes</i> , 2017 , 8,	4.2	21
136	Treatment challenges in and outside a network setting: Head and neck cancers. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 40-45	3.6	21
135	Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040) 2019 , 7, 96		20
134	Radiotherapy for unresectable sinonasal cancers: dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. <i>Radiotherapy and Oncology</i> , 2014 , 113, 260-6	5.3	20
133	A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?. <i>Current Opinion in Oncology</i> , 2006 , 18, 253-7	4.2	20
132	Cancer of the anal region. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 43, 77-92	7	20
131	The EORTC module for quality of life in patients with thyroid cancer: phase III. <i>Endocrine-Related Cancer</i> , 2017 , 24, 197-207	5.7	19
130	Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. <i>Annals of Oncology</i> , 2015 , 26, 1248-1253	10.3	19
129	Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2016 , 52, 18-23	4.4	19
128	Hope in cancer patients: the relational domain as a crucial factor. <i>Tumori</i> , 2015 , 101, 447-54	1.7	19
127	Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. <i>Annals of Oncology</i> , 2010 , 21, 1952-1960	10.3	19
126	Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1886-93	10.3	19
125	Which classification for ethmoid malignant tumors involving the anterior skull base?. <i>Head and Neck</i> , 2005 , 27, 224-31	4.2	19
124	Salivary gland cancer: an update on present and emerging therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 257-63	7.1	18
123	Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1521-7	4.2	18
122	Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. <i>BMC Cancer</i> , 2014 , 14, 473	4.8	17

121	Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014 , 15, 678-82	4.6	17
120	Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis. <i>Annals of Oncology</i> , 2012 , 23, 1825-32	10.3	17
119	Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. <i>Oral Oncology</i> , 2005 , 41, 97-8	4.4	17
118	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. <i>Oral Oncology</i> , 2018 , 86, 266-272	4.4	17
117	Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile. <i>Journal of Clinical Oncology</i> , 2012 , 30, 564-5; 565-567	2.2	16
116	Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii200-3	10.3	16
115	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2359-2366	2.2	16
114	A pilot study of a smartphone-based monitoring intervention on head and neck cancer patients undergoing concurrent chemo-radiotherapy. <i>International Journal of Medical Informatics</i> , 2019 , 129, 404-412	5.3	15
113	Quality of life assessment and clinical decision-making. <i>Annals of Oncology</i> , 1997 , 8, 1207-11	10.3	15
112	Head and neck tumors other than squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2004 , 16, 236-41	4.2	15
111	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. <i>Cancers</i> , 2020 , 12,	6.6	15
110	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. <i>Oral Oncology</i> , 2017 , 69, 33-37	4.4	14
109	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. <i>Oral Oncology</i> , 2014 , 50, 884-7	4.4	14
108	TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. <i>Translational Oncology</i> , 2008 , 1, 121-8	4.9	14
107	Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosis. <i>Oral Oncology</i> , 2002 , 38, 401-4	4.4	14
106	Transcriptomics and Epigenomics in head and neck cancer: available repositories and molecular signatures. <i>Cancers of the Head & Neck</i> , 2020 , 5, 2	5.9	13
105	Multikinase inhibitors in thyroid cancer. <i>European Journal of Cancer</i> , 2010 , 46, 1012-8	7.5	13
104	Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2013 , 35, 1471-4	4.2	13

103	Timing of chemoradiotherapy and patient selection for locally advanced nasopharyngeal carcinoma. <i>Clinical Oncology</i> , 2003 , 15, 451-60	2.8	13
102	Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. <i>Radiologia Medica</i> , 2019 , 124, 414-421	6.5	13
101	Immunohistochemical and molecular profile of salivary gland cancer in children. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26468	3	12
100	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. <i>Otolaryngology - Head and Neck Surgery</i> , 2019 , 161, 635-642	5.5	12
99	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	12
98	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019 , 41, 3670-3676	4.2	12
97	START: a European state-of-the-art on-line instrument for clinical oncologists. <i>Annals of Oncology</i> , 1999 , 10, 769-73	10.3	12
96	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 171-181	9.7	12
95	Immunotherapy for recurrent/metastatic head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018 , 26, 152-156	2	11
94	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. <i>Oral Oncology</i> , 2018 , 82, 144-151	4.4	11
93	Fosbretabulin for the treatment of anaplastic thyroid cancer. <i>Future Oncology</i> , 2014 , 10, 2015-21	3.6	10
92	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. <i>Laryngoscope</i> , 2020 , 130, 857-865	3.6	10
91	Different View on Larynx Preservation Evidence-Based Treatment Recommendations. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1376-1377	2.2	10
90	Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	9
89	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019 , 123, 138-145	7.5	9
88	Targeted therapy in head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2011 , 19, 132-7	2	9
87	Forecasting the performance status of head and neck cancer patient treatment by an interval arithmetic pruned perceptron. <i>IEEE Transactions on Biomedical Engineering</i> , 2002 , 49, 782-7	5	9
86	Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. <i>Frontiers in Oncology</i> , 2019 , 9, 837	5.3	8

85	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , 2020 , 136, 35-42	7.5	8
84	Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. <i>Targeted Oncology</i> , 2018 , 13, 253-256	5	8
83	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. <i>Clinical and Translational Radiation Oncology</i> , 2018 , 12, 47-52	4.6	8
82	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. <i>Cancer Letters</i> , 2015 , 359, 269-74	9.9	8
81	Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. <i>Annals of Oncology</i> , 1997 , 8, 1157-8	10.3	8
80	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. <i>Value in Health</i> , 2017 , 20, 799-808	3.3	7
79	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. <i>Oral Oncology</i> , 2019 , 90, 94-101	4.4	7
78	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. <i>European Journal of Cancer</i> , 2018 , 93, 89-98	7.5	7
77	Benefits and Risks of Machine Learning Decision Support Systems. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 2354	27.4	7
76	Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. <i>Future Oncology</i> , 2015 , 11, 1429-35	3.6	7
75	Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2012 , 67, e226-8	4.5	7
74	Advances in the changing patterns of aetiology of head and neck cancers. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006 , 14, 95-9	2	7
73	Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project. <i>Head and Neck</i> , 2021 , 43, 601-612	4.2	7
72	Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation. <i>Supportive Care in Cancer</i> , 2015 , 23, 3465-72	3.9	6
71	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 734-45	3.3	6
70	Emerging tyrosine kinase inhibitors for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 445-59	3.7	6
69	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. <i>European Journal of Cancer</i> , 2021 , 159, 194-204	7.5	6
68	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. <i>Cells</i> , 2020 , 9,	7.9	6

67	Personalized Medicine and the Contradictions and Limits of First-Generation Deescalation Trials in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018 , 144, 99-100	3.9	6
66	Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. <i>Head and Neck</i> , 2018 , 40, 2648-2656	4.2	6
65	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100468	2.2	6
64	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 435-443	5.9	5
63	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. <i>Dysphagia</i> , 2019 , 34, 52-62	3.7	5
62	PD-1 immunotherapy for recurrent or metastatic HNSCC. <i>Lancet, The</i> , 2019 , 394, 1882-1884	4.0	5
61	Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7757-8; author reply 7758-9	2.2	5
60	Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016 , 38 Suppl 1, E1009-13	4.2	5
59	Identification of potentially druggable molecular alterations in skin adnexal malignancies. <i>Journal of Dermatology</i> , 2019 , 46, 507-514	1.6	4
58	Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuited to Receive Cisplatin-Based Therapy. <i>Frontiers in Oncology</i> , 2019 , 9, 1522	5.3	4
57	Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. <i>Medical Oncology</i> , 2016 , 33, 76	3.7	4
56	How many therapeutic options are there for recurrent or metastatic salivary duct carcinoma?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 672; author reply 672-673	2.2	4
55	Biological agents in head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1643-50	3.5	4
54	Antiemetic therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 43, 93-101	7	4
53	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 518110	5.3	4
52	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). <i>Oncology</i> , 2020 , 98, 763-770	3.6	4
51	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. <i>Oral Oncology</i> , 2019 , 97, 82-91	4.4	3
50	Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for rethinking treatment strategies?. <i>Thyroid</i> , 2014 , 24, 1815	6.2	3

49	Oral prevalence and clearance of oncogenic human papilloma virus in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?. <i>Journal of Oral Pathology and Medicine</i> , 2015 , 44, 728-33	3.3	3
48	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. <i>Future Oncology</i> , 2014 , 10, 2111-20	3.6	3
47	Biological agents in head and neck cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x45-8	10.3	3
46	Chemoradiation therapy in locally advanced nasopharyngeal cancer: which kind of cooperation?. <i>Annals of Oncology</i> , 2003 , 14, 508-9	10.3	3
45	The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying-the head and neck cancer model. <i>Cancer Causes and Control</i> , 2021 , 32, 459-471	2.8	3
44	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021 , 43, 2844-2858	4.2	3
43	Data Set for the Reporting of Carcinomas of the Nasal Cavity and Paranasal Sinuses: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting. <i>Archives of Pathology and Laboratory Medicine</i> , 2019 , 143, 424-431	5	3
42	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. <i>Tumori</i> , 2020 , 106, 39-46	1.7	3
41	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. <i>Disease Markers</i> , 2017 , 2017, 6870614	3.2	2
40	Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. <i>Tumori</i> , 2018 , 104, 213-220	1.7	2
39	Folate in head and neck squamous cell cancer chemoprevention: purposely left out?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3463; author reply 3463-4	2.2	2
38	Treatment of Cancer of the Base of the Tongue and Glosso-Epiglottic Region: A Multicenter Italian Survey. <i>Tumori</i> , 2000 , 86, 215-223	1.7	2
37	The Multidisciplinary Approach in Clinical Oncology. <i>Tumori</i> , 1998 , 84, 279-280	1.7	2
36	Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6027-6027	2.2	2
35	Treatment Options for Recurrent Anterior Skull Base Tumors. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 231-245	1.7	2
34	Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , 2020 , 2020, 1152-1155	0.9	2
33	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016 , 58, e4-5	4.4	2
32	Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.. <i>Future Oncology</i> , 2022 ,	3.6	2

31	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , 2019 , 41, 2517-2528.e28	3.5	1
30	Comments on "postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure" by Chan and Coll. <i>Oral Oncology</i> , 2013 , 49, e38	4.4	1
29	Head and neck cancer. <i>Journal of Oncology</i> , 2009 , 2009, 358098	4.5	1
28	TP53 mutations in head and neck cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 1194; author reply 1195	59.2	1
27	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021 , 158, 17-26	7.5	1
26	The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2020 , 84, 78-86	1.7	1
25	Local therapies for liver metastases of rare head and neck cancers: a monoinstitutional case series. <i>Tumori</i> , 2021 , 107, 188-195	1.7	1
24	Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. <i>Cancers</i> , 2020 , 12,	6.6	1
23	The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS6090-TPS6090	2.2	1
22	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. <i>Acta Oncologica</i> , 2021 , 60, 1192-1200	3.2	1
21	The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6066-6066	2.2	1
20	Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale. <i>Quality of Life Research</i> , 2021 , 30, 117-124	3.7	1
19	Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. <i>Tumori</i> , 2016 , 102,	1.7	1
18	An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma.. <i>JCO Precision Oncology</i> , 2021 , 5, 1526-1527	3.6	1
17	Nasal cavity and paranasal sinus586-596		1
16	Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel. <i>Tumori</i> , 2019 , 300891619868289 ^o	1.7	
15	Systemic Therapy in Salivary Gland Carcinoma 2019 , 213-224		
14	Comment on 'Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'. <i>British Journal of Cancer</i> , 2015 , 113, 1638-9	8.7	

- 13 Carcinoma anaplastico della tiroide. *L Endocrinologo*, **2012**, 13, 216-220 0
- 12 From chemoprevention and organ preservation programs to post-operative management: major achievements and strategies of the EORTC Head and Neck Cancer Group. *European Journal of Cancer, Supplement*, **2012**, 10, 76-81 1.6
- 11 Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll. *Oral Oncology*, **2010**, 46, 888; author reply 889-90 4.4
- 10 Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. *Oral Oncology*, **2005**, 41, 219-221
- 9 When Everything Revolves Around Internal Carotid Artery: Analysis of Different Management Strategies in Patients With Very Advanced Cancer Involving the Skull Base. *Frontiers in Oncology*, **2021**, 11, 781205 5.3
- 8 Radiotherapy and Medical Treatment **2020**, 47-56
- 7 Management of Salivary Gland Cancer **2016**, 625-640
- 6 Nasal Cavity and Paranasal Sinus 586-596
- 5 Management of Salivary Gland Cancer **2011**, 521-532
- 4 Tumori maligni epiteliali dell'orofaringe **2011**, 309-319
- 3 Next generation platinum salt in nasopharyngeal carcinoma. *Lancet Oncology, The*, **2021**, 22, 577-578 21.7
- 2 Malignant salivary gland tumours in families with breast cancer susceptibility. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 221-226 5.1
- 1 New Data on Systemic Therapy of Salivary Gland Tumors **2018**, 277-284